DaVita: Comprehensive Provider for Kidney Health Surprises with 33% Profit Forecast - P/E Ratio Drops to About 8!
Reading Time: 2 minutes
DaVita (DVA) is considered a leading healthcare provider in nephrology, offering dialysis services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). It operates 3,247 outpatient dialysis centers, with 25% of approximately 293,000 patients also utilizing the more profitable home dialysis. Although US dialysis volume showed a decline of 1.1% last year, CEO Javier Rodriguez is convinced of growth of at least 2% in the medium term. Influenza vaccinations, GLP-1 medications, and new filters are improving patient outcomes,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
